UB Paderborn / Katalog / Suche / in CDI

Bevacizumab plus FOLFIRI after failure of platinum–etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial

The lancet oncology, 2023-03, Vol.24 (3), p.297-306

2023

Link zum Volltext

Verfügbarkeit prüfen

Prognostic value of sarcopenia in patients treated by Radiochemotherapy for locally advanced oesophageal cancer

Radiation oncology (London, England), 2020-05, Vol.15 (1), p.116-9, Article 116

2020

Link zum Volltext

Verfügbarkeit prüfen

Cell-free DNA and circulating TERT promoter mutation for disease monitoring in newly-diagnosed glioblastoma

Acta neuropathologica communications, 2020-11, Vol.8 (1), p.179-10, Article 179

2020

Link zum Volltext

Verfügbarkeit prüfen

Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study)

Clinical cancer research, 2017-09, Vol.23 (18), p.5416-5425

2017

Link zum Volltext

Verfügbarkeit prüfen

Benefit of cetuximab addition to a platinum–fluorouracil-based chemotherapy according to KRAS-LCS6 variant in an unselected population of recurrent and/or metastatic head and neck cancers

European archives of oto-rhino-laryngology, 2019-02, Vol.276 (2), p.541-550

2019

Link zum Volltext

Verfügbarkeit prüfen

Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan

Journal of clinical oncology, 2009-03, Vol.27 (7), p.1122-1129

2009

Link zum Volltext

Verfügbarkeit prüfen

TERT Promoter Alterations in Glioblastoma: A Systematic Review

Cancers, 2021-03, Vol.13 (5), p.1147

2021

Link zum Volltext

Verfügbarkeit prüfen

Predictive value of initial FDG-PET features for treatment response and survival in esophageal cancer patients treated with chemo-radiation therapy using a random forest classifier

PloS one, 2017-03, Vol.12 (3), p.e0173208-e0173208

2017

Link zum Volltext

Verfügbarkeit prüfen

Circulating PIK3CA mutation detection at diagnosis in non-metastatic inflammatory breast cancer patients

Scientific reports, 2021-12, Vol.11 (1), p.24041-24041, Article 24041

2021

Link zum Volltext

Verfügbarkeit prüfen

The Day after Tomorrow: How Should We Address Health System Organization to Treat Cancer Patients after the Peak of the COVID-19 Epidemic?

Oncology, 2020-11, Vol.98 (12), p.827-835

2020

Link zum Volltext

Verfügbarkeit prüfen

Circulating ESR1 mutations at the end of aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients

Breast cancer research : BCR, 2018-05, Vol.20 (1), p.40-5, Article 40

2018

Link zum Volltext

Verfügbarkeit prüfen

Clinical relevance of circulating ESR1 mutations during endocrine therapy for advanced hormone-dependent endometrial carcinoma

BMC cancer, 2023-11, Vol.23 (1), p.1-1061, Article 1061

2023

Link zum Volltext

Verfügbarkeit prüfen

Circulating DNA changes are predictive of disease progression after transarterial chemoembolization

International journal of cancer, 2022-02, Vol.150 (3), p.532-541

2022

Link zum Volltext

Verfügbarkeit prüfen

Short report: Monitoring ESR1 mutations by circulating tumor DNA in aromatase inhibitor resistant metastatic breast cancer

International journal of cancer, 2015-11, Vol.137 (10), p.2513-2519

2015

Link zum Volltext

Verfügbarkeit prüfen

Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer

Breast cancer research : BCR, 2020-05, Vol.22 (1), p.56-56, Article 56

2020

Link zum Volltext

Verfügbarkeit prüfen

Impact of Taxanes, Endocrine Therapy, and Deleterious Germline BRCA Mutations on Anti-müllerian Hormone Levels in Early Breast Cancer Patients Treated With Anthracycline- and Cyclophosphamide-Based Chemotherapy

Frontiers in oncology, 2019-07, Vol.9, p.575-575

2019

Link zum Volltext

Verfügbarkeit prüfen

ESR1 mutations in breast cancer

Aging (Albany, NY.), 2017-01, Vol.9 (1), p.3-4

2017

Link zum Volltext

Verfügbarkeit prüfen

Impact of new generation hormone-therapy on cognitive function in elderly patients treated for a metastatic prostate cancer: Cog-Pro trial protocol

BMC cancer, 2017-08, Vol.17 (1), p.549-549, Article 549

2017

Link zum Volltext

Verfügbarkeit prüfen

Comparison of the quantification of KRAS mutations by digital PCR and E-ice-COLD-PCR in circulating-cell-free DNA from metastatic colorectal cancer patients

Clinica chimica acta, 2017-02, Vol.465, p.1-4

2017

Link zum Volltext

Verfügbarkeit prüfen

Prognostic value of circulating short-length DNA fragments in unresected glioblastoma patients

Translational oncology, 2024-04, Vol.42, p.101897-101897, Article 101897

2024

Link zum Volltext

Verfügbarkeit prüfen

Deleterious impact of a generic temozolomide formulation compared with brand‐name product on the kinetic of platelet concentration and survival in newly diagnosed glioblastoma

Fundamental & clinical pharmacology, 2020-08, Vol.34 (4), p.484-494

2020

Link zum Volltext

Verfügbarkeit prüfen

Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls

Modern pathology, 2011-08, Vol.24 (8), p.1090-1100

2011

Link zum Volltext

Verfügbarkeit prüfen

Analysis of the allele-specific expression of the mismatch repair gene MLH1 using a simple DHPLC-Based Method

Human mutation, 2004-04, Vol.23 (4), p.379-384

2004

Link zum Volltext

Verfügbarkeit prüfen

FOLFIRINOX relative dose intensity and disease control in advanced pancreatic adenocarcinoma

Therapeutic advances in medical oncology, 2021, Vol.13, p.175883592110298-17588359211029825

2021

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Bevacizumab plus FOLFIRI after failure of platinum–etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial

Prognostic value of sarcopenia in patients treated by Radiochemotherapy for locally advanced oesophageal cancer

Cell-free DNA and circulating TERT promoter mutation for disease monitoring in newly-diagnosed glioblastoma

Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study)

Benefit of cetuximab addition to a platinum–fluorouracil-based chemotherapy according to KRAS-LCS6 variant in an unselected population of recurrent and/or metastatic head and neck cancers

Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan

TERT Promoter Alterations in Glioblastoma: A Systematic Review

Predictive value of initial FDG-PET features for treatment response and survival in esophageal cancer patients treated with chemo-radiation therapy using a random forest classifier

Circulating PIK3CA mutation detection at diagnosis in non-metastatic inflammatory breast cancer patients

The Day after Tomorrow: How Should We Address Health System Organization to Treat Cancer Patients after the Peak of the COVID-19 Epidemic?

Circulating ESR1 mutations at the end of aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients

Clinical relevance of circulating ESR1 mutations during endocrine therapy for advanced hormone-dependent endometrial carcinoma

Circulating DNA changes are predictive of disease progression after transarterial chemoembolization

Short report: Monitoring ESR1 mutations by circulating tumor DNA in aromatase inhibitor resistant metastatic breast cancer

Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer

Impact of Taxanes, Endocrine Therapy, and Deleterious Germline BRCA Mutations on Anti-müllerian Hormone Levels in Early Breast Cancer Patients Treated With Anthracycline- and Cyclophosphamide-Based Chemotherapy

ESR1 mutations in breast cancer

Impact of new generation hormone-therapy on cognitive function in elderly patients treated for a metastatic prostate cancer: Cog-Pro trial protocol

Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor

Comparison of the quantification of KRAS mutations by digital PCR and E-ice-COLD-PCR in circulating-cell-free DNA from metastatic colorectal cancer patients

Prognostic value of circulating short-length DNA fragments in unresected glioblastoma patients

Deleterious impact of a generic temozolomide formulation compared with brand‐name product on the kinetic of platelet concentration and survival in newly diagnosed glioblastoma

Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls

Analysis of the allele-specific expression of the mismatch repair gene MLH1 using a simple DHPLC-Based Method

FOLFIRINOX relative dose intensity and disease control in advanced pancreatic adenocarcinoma

Suchergebnisse filtern